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Novel microbes are either newly isolated genera and species from natural sources or
bacterial strains derived from existing bacteria. Novel microbes are gaining increasing
attention for the general aims to preserve and modify foods and to modulate gut
microbiota. The use of novel microbes to improve health outcomes is of particular
interest because growing evidence points to the importance of gut microbiota in
human health. As well, some recently isolated microorganisms have promise for use as
probiotics, although in-depth assessment of their safety is necessary. Recent examples
of microorganisms calling for more detailed evaluation include Bacteroides xylanisolvens,
Akkermansia muciniphila, fructophilic lactic acid bacteria (FLAB), and Faecalibacterium
prausnitzii. This paper discusses each candidate’s safety evaluation for novel food or
novel food ingredient approval according to European Union (EU) regulations. The factors
evaluated include their beneficial properties, antibiotic resistance profiling, history of
safe use (if available), publication of the genomic sequence, toxicological studies in
agreement with novel food regulations, and the qualified presumptions of safety. Sufficient
evidences have made possible to support and authorize the use of heat-inactivated B.
xylanisolvens in the European Union. In the case of A. muciniphila, the discussion focuses
on earlier safety studies and the strain’s suitability. FLAB are also subjected to standard
safety assessments, which, along with their proximity to lactic acid bacteria generally
considered to be safe, may lead to novel food authorization in the future. Further research
with F. prausnitzii will increase knowledge about its safety and probiotic properties
and may lead to its future use as novel food. Upcoming changes in EUU Regulation
2015/2283 on novel food will facilitate the authorization of future novel products and
might increase the presence of novel microbes in the food market.
Keywords: novel microbes, safety, Bacteroides xylanisolvens, Akkermansia muciniphila, fructophilic lactic acid
bacteria, Faecalibacterium prausnitzii
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INTRODUCTION
Since ancient times, microorganisms have constituted an
essential part of human nutrition and been consumed through
naturally microbially fermented products containing viable
bacteria, such as fermented honey, fruits, berries, and their juices
and fermented products of animal origin. Without even knowing
of the existence of bacteria, humans historically used them to
initiate many food production processes (Selhub et al., 2014).
Today, an enormous variety of fermented foods and beverages
exists and provides approximately one-third of the human
diet globally (Borresen et al., 2012). Certain fermented foods
containing significant amounts of viable microbes, especially
dairy products and fermented vegetables, are part of daily
consumption by millions of people around the globe.
Studies involving new analytical technologies have generated
new insights into the human and animal guts and yielded
new isolates and candidates that perform special functions
in this complex intestinal environment (Marchesi et al.,
2016). The composition of human gut microbiota plays an
important role in homeostasis and gut functionality, which are
also strongly influenced by age, diet, environmental factors,
disorders, diseases, and therapies. In recent decades, probiotic
microorganisms have been identified as efficient modulators
of intestinal microbial balance (Gómez-Gallego and Salminen,
2016). Probiotics are defined as live microorganisms that confer
a health benefit to the host when administered in adequate
amounts (Cammarota et al., 2014; Hill et al., 2014). These health
benefits are provided through relatively common mechanisms
found in the vast majority of the investigated probiotics, such
as regulation of the intestinal transit, competitive exclusion
of pathogens, and production of specific short chain fatty
acids (SCFA). In addition, frequently observed mechanisms
mostly found on a species level include vitamin synthesis,
enzymatic activity, gut barrier reinforcement, and neutralization
of carcinogens. The existence of a group of basic benefits
shared by strains of the same species in a non-strain specific
manner supports the concept of core benefits for specific
species. Moreover, mechanisms described exclusively on the
individual strain level provide immunological, neurological, and
endocrinological effects. Such benefits in general support a
healthy digestive tract and immune system (Aureli et al., 2011;
Gómez-Gallego and Salminen, 2016).
Traditionally fermented foods, especially fermented dairy
products, usually contain viable bacteria. The consumption
of such foods is widely connected with the reduction of
certain disease types (e.g., childhood obesity, type-2 diabetes,
and cardiovascular diseases), improved body composition, and
weight loss in adults during energy restriction (Thorning et al.,
2016). The International Scientific Association for Probiotics
and Prebiotics (ISAPP) panel acknowledged convincing results
but also emphasized the difficulty of verifying whether the
beneficial results originate from the food matrices, the (viable)
microorganisms, or a combination of both. Additionally,
traditional fermented foods do not qualify for the term
probiotic because they may contain varying amounts and
changing microbial species over time, and their microbiological
composition is not completely known or controlled. A relevant
example is traditional Kefir. The ISAPP, therefore, has proposed
the term “containing live and active bacterial cultures” for
traditional fermented foods (Hill et al., 2014).
Probiotics relevant to the human gut microbiota mainly
belong to the genera Lactobacillus and Bifidobacterium, but
several other microbial candidates, such as Akkermansia
muciniphila and Faecalibacterium prausnitzii, could play roles in
future probiotic products. Although, commensal gut microbes
can provide beneficial health effects, the ISAPP panel suggested
conducting strain-by-strain assessment until sufficient research
data are available to grant probiotic status on the species level
(Hill et al., 2014).
EUROPEAN UNION REGULATIONS OF
MICROORGANISMS INTENTIONALLY
ADDED TO FOOD
The European Union (EU) is a single-market system consisting
of 28 member states and the four members of the European
Free Trade Association (Iceland, Liechtenstein, Norway, and
Switzerland), which are required to follow European legislation
as part of the EU single market. The European Food Safety
Authority (EFSA) has the mandate to assess and communicate
all risks associated with the food chain in the EU. The EFSA
Scientific Committees and Panels are responsible for providing
scientific opinions in response to requests from the European
Commission, European Parliament, and EU member states.
Before the EFSA was established, risk assessment was performed
by Scientific Committees assisting the Directorate General for
Health and Consumers (DG SANCO). DG SANCO, re-named
to DG SANTE, continues to perform a crucial regulatory
role regarding microorganisms in food and feed. Standing
Committees representing member states, and their interests have
strong influence on the work of DG SANTE (von Wright, 2012).
Amid globalization and ongoing technical progress, the
number of new food products in the EU has increased
significantly, and food safety has become a growing concern.
A uniform regulation for novel food was needed to ensure
the protection of both European consumers and the market.
The introduction of novel foods is governed by Regulation
285/97/EC (European Commission, 1997b) and Regulation
2015/2283 (European Commission, 2015), covering all foods not
been used in the EU before 15 May 1997. Under Regulation
2015/2283, the EFSA, rather than competent national authorities,
will perform the scientific risk assessment for novel foods; the
system of individual authorization is replaced by a system of
generic authorization; and the Commission will manage all
applicants’ files and prepares proposals for the authorization of
novel foods found to be safe (European Commission, 2015). To
speed decision-making, the EFSA is required to issue its opinion
within 9 months of the date of receipt of a valid application.
The guidance lists general requirements for every application:
(1) a description; (2) compositional data; (3) production process;
(4) specifications; (5) proposed uses and use levels; and (6)
anticipated intake of the novel food. Applicants also have
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to provide information about the absorption, distribution,
metabolism, excretion, nutrition, toxicology, allergenicity, and
history of use of novel foods or their source. In addition, all
the novel foods that belong to the group of “foods consisting
of, isolated from or produced from micro-organisms, fungi or
algae” must provide the following information (EFSA Panel on
Dietetic Products, 2016): (1) scientific (Latin) name (family,
genus, species, strain) according to the international codes
of nomenclature; (2) synonyms used interchangeably with the
preferred scientific name; (3) for bacteria and yeasts (unicellular
organisms), verification of the species and strain identity
according to internationally accepted methods; (4) origin of
the organism; and (5) if available, deposition in an officially
recognized culture collection with an access number.
Qualified Presumption of Safety
EFSA introduced the concept of qualified presumption of safety
(QPS) to establish a generic risk assessment approach for
biological agents, with the goal to simplify and harmonize
assessment of notified biological agents across the EFSA’s various
Scientific Panels and Units. The QPS approach also enables
more focused application of the available resources to agents
with higher risk potential (Leuschner et al., 2010), simplifying
the assessment of low-risk microorganisms. The QPS concept
is intended to establish a safety assessment for microorganisms
used in feed and food production. If a specific strain notified
for market authorization can unambiguously be connected to a
taxonomic unit on the QPS list, the necessary safety assessment
steps, if any, are indicated in the list for that taxonomic unit.
Bacteria with a previous history of safe use are usually
included on the QPS list. The EFSA’s Panel on Biological Hazards
assesses the QPS status of a strain and declares that the assigned
microorganism displays either no safety concerns or minor
concerns defined and addressed with qualifications as expressed
in the QPS list. Microorganisms on the QPS list, therefore, need
no exhaustive safety assessment except for those specified in the
QPS list.
The assessment for QPS suitability is well structured and relies
on the following criteria (EFSA, 2007):
(a) Taxonomic unit: This is the most crucial part of the
assessment procedure. The genus and all known species,
including type species, are listed and described according
to their main characteristics. The evaluated taxonomic unit
must be unambiguously defined. If the assessed bacterial
agent cannot be connected to any known species, it will not
be recommended for the QPS list. QPS status is also denied
if the taxonomic identification is insufficient.
(b) Body of knowledge: This should be related to the history of
use for the assessed bacterial agent, the field of application,
the existence of sufficient scientific literature about the
microorganism, and the possibility to avoid potential adverse
effects for humans, livestock, and the wider environment.
(c) Possible pathogenicity: The bacterial agent’s lack of
pathogenic and virulence properties is confirmed, and the
findings must be supported by clinical data and scientific
literature.
(d) Description of end use: This includes the presence and
viability of the microorganism in the final product.
Most bacteria recommended for the QPS list belong to the group
of Gram-positive non-sporulating bacteria. This group includes
many inhabitants of the digestive tract with long histories in
food and feed production. For this group, the EFSA’s Scientific
Committee applies a generic qualification for all taxonomic units
on the list, requiring that all strains not carry any transferable
antimicrobial resistance unless the final product contains no
viable cells (Leuschner et al., 2010). The number of recommended
Gram-negative bacteria is very low, with only one, Gluconobacter
oxydans, on the QPS list. Many members have a long history of
safe use, but safety concerns cannot be excluded. E. coli strain
Nissle 1917, for example, has long been used as a probiotic but
can cause a variety of diseases and exhibits versatile virulence
mechanisms. Nevertheless, opportunistic bacteria may be placed
on the QPS list with additional qualifications, but pathogenic and
toxin-producing bacteria are not included.
Microorganisms whose safety properties are not fully
understood are subjected to safety assessments. Such assessments
need to include a distinct taxonomic classification on the species
or the strain level and a comprehensive strain characterization,
including whole-genome sequence analysis, to identify potential
virulence and antibiotic resistance genes and their horizontal
transfer capabilities. However, in the case of new and recently
discovered microorganisms from previously unknown microbial
groups, the availability of genome sequencesmight not be enough
to identify potential virulence or antibiotic resistance genes.
These often require comparison with available data, so functional
studies on these microorganisms are needed. For accurate safety
evaluation, the food business operator should include the number
and the viability of microorganisms in the final product by.
The QPS approach was inspired and influenced by the
American Generally Recognized As Safe (GRAS) concept, but
differences exist. QPS is defined as an “assumption based
on reasonable evidence” (H. C. P. Directorate-General, 2003),
providing a helpful assessment tool for the EFSA but, in contrast
to GRAS, offers no legal status. The EFSA is responsible for
providing the burden of proof, while GRAS lays the responsibility
on the food business operator. GRAS, though, requires safety
assessment by independent experts to the degree that another
panel of independent experts would reach the same conclusions.
The QPS assessment’s strong focus on the absence of acquired
antibiotic resistances and virulence factors is another difference
between the two concepts.
MICROORGANISMS AUTHORIZED AS
NOVEL FOOD IN THE EU
Leuconostoc mesenteroides
In January 2001, the European Commission authorized market
placement of a dextran preparation produced by L. mesenteroides
as a novel food ingredient in bakery products. Puracor NV
(Groot-Bijgaarden, Belgium) filed the application, and the
Belgian competent authorities performed the initial assessment.
The Scientific Committee for Food found that the dextran
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preparation by L. mesenteroideswas safe for human consumption
up to 5% in bakery products. Dextran was identified as a highly
digestible bakery ingredient with similar nutritional properties as
starch (European Commission, 2001).
L. mesenteroides is a Gram-positive, non-sporulating, coccoid-
shaped bacterium in the order Lactobacillales. The organism
is often found on the surfaces of various plant parts and
is responsible for the fermentation of white cabbage into
sauerkraut. L. mesenteroides can be also found in artisanal and
industrial cheeses, possibly contributing to their safety for long-
term consumption (Cibik et al., 2000; D’Angelo et al., 2017). The
species can metabolize a broad range of sugars; in particular,
sucrose is used to build dextran, and certain strains can produce
bacteriocins with anti-listerial activity (de Paula et al., 2015).
Bacillus subtilis Natto
In April 2009, the European Commission allowed placing
Vitamin K2 (menaquinone), produced by B. subtilis natto, in the
market as a novel food ingredient under Regulation (EC) No
258/97. NattoPharma (Oslo, Norway) requested that the Irish
competent authorities place B. subtilis natto derived Vitamin
K2 in the market as a novel food ingredient to be used in
foods which served particular nutritional uses and which had
added vitamins and minerals (European Commission, 2009). In
an initial report, the Irish competent authorities required an
additional assessment, so the EFSA was requested to conduct an
extended assessment. The Scientific Panel on Dietetic Products,
Nutrition, and Allergies concluded that B. subtilis natto is a safe
source of vitamin K2.
B. subtilis natto is a Gram-positive, aerobic member of the
spore-forming genus Bacillus. This species, discovered in Japan
in 1906, is responsible for production of natto, a sticky fermented
soy beans. Natto, produced by B. subtilis natto, has long been used
in the Japanese diet, so it gained Foods for Specified Health Use
approval based on its health benefits from the Japanese Ministry
of Health, Labor, andWelfare. B. subtilis has a recognized history
of safe use, so the EFSA granted it QPS status (EFSA Panel on
Biological Hazards, 2010).
Clostridium butyricum
In December 2014, the European Commission authorized
placing in the market C. butyricum CBM 588 as a novel
food ingredient according to Regulation (EC) No 258/97
(European Commission, 2014). The British competent
authorities performed the initial assessment after Miyarisan
Pharmaceutical Co. Ltd. (Tokyo, Japan) requested using C.
butyricum on the market as a novel food ingredient used in food
supplements. Some beneficial effects reported for C. butyricum
are related to the production of SCFA and its role in lipid
metabolism (Zhao et al., 2014; Shang et al., 2016). No additional
assessment was necessary because further explanations provided
by the applicant addressed the objections raised by member
states. C. butyricum was authorized as novel food ingredient
in food supplements at a maximum dose of 1.35 × 108 CFU
per day. Intervention studies revealed the health benefits of
the strain, including prevention of pouchitis in patients with
ulcerative colitis and decreased incidence of side effects in
patients receiving therapy for the eradication of Helicobacter
pylori (Shimbo et al., 2005; Yasueda et al., 2016). An antibiotic
resistance profile, a study for genes encoding toxins, and an
animal study were conducted to ensure the safety of the strain
(Isa et al., 2016). The authorized strain is a Gram-positive, spore-
forming, obligate aerobic, non-pathogenic, non-genetically
modified organism. The product is characterized as a white or
pale gray tablet with a specific odor and sweet taste (European
Commission, 2014).
Bacteroides xylanisolvens
The most recent authorization for bacteria according to
Regulation (EC) No 258/97 was granted in 2015. The European
Commission approved placing pasteurized milk products
fermented with B. xylanisolvens DSM 23964 in the market as a
novel food in a heat-treated, non-viable form. Details concerning
B. xylanisolvens are discussed in the following section.
NOVEL MICROBES: DETAILS AND
BACKGROUND REGARDING SAFETY
Bacteroides xylanisolvens DSM 23964
In 2015, pasteurized milk products fermented with
B. xylanisolvens DSM 23964 were approved as a novel food
under Novel Food Regulation No 258/97. Usage of this specific
strain was restricted as the starter culture in the fermentation
of pasteurized milk products. Only heat-treated and therefore
inactivated cells of B. xylanisolvens were allowed in the final
product (EFSA Panel on Dietetic Products, Nutrition and
Allergies, 2015). In addition to the novel food evaluation, the
EFSA automatically assessed B. xylanisolvens for admission to
the QPS list. Interestingly, the EFSA revealed that the available
information was not sufficient to include it in the QPS list.
The genus Bacteroides is a main inhabitant of the human
colon, on average accounting for ∼30% of intestinal microbiota,
although large inter-individual variability exists (Sears, 2005).
Bacteroides spp. is a Gram-negative, obligately anaerobic, bile
resistant, non-spore forming rod originally isolated from human
stool. This genus can have commensal attributes within the
human body but can also promote the development of different
diseases. Bacteroides xylanisolvens plays a major part in the
fermentation and degradation of xylan and other plant fibers
(Chassard et al., 2008). Bacteroides start colonization of the gut
in the newborn child ∼10 days after birth, (Gregory et al., 2015).
Polysaccharides in the human diet are an important nutrition
source for gut commensals, including Bacteroides spp. They can
be metabolized into short chain fatty acids and branched chain
fatty acids that are reabsorbed through the large intestine and
provide an essential part of the host’s daily required energy
(Hooper et al., 2002).
The levels of Bacteroidetes and Firmicutes seem to be
connected to obesity. Obese individuals show lower levels of
Bacteroidetes and higher levels of Firmicutes in the gastro-
intestinal tract. Turnbaugh and his colleagues (Turnbaugh et al.,
2006) suggested that a higher Bacteroidetes/Firmicutes ratio
can extract more energy from a given diet and that increased
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Bacteroidetes levels in the gut led to weight loss in people with
obesity.
While investigating xylan-degrading microorganisms in the
human gastro-intestinal tract, Chassard et al. (2008) isolated
6 xylanolytic, Gram-negative anaerobic rods. Subsequent 16S
rRNA analysis revealed that the obtained strains belonged to the
genus Bacteroides, and after proper analysis, the 6 strains were
considered to be novel species, and the researchers proposed the
name B. xylanisolvens based on their xylan-degrading properties.
The main characteristics of the designated type strain are shown
in Table 1.
The German Federal Institute for Occupational Safety in
Health (Bundesanstalt für Arbeitsschutz und Arbeitsmedizin,
BAuA) assessed the safety of B. xylanisolvens as a working
material (BAuA, 2011). Due to the lack of pathogenicity and
diseases, the agency classified the microorganism in the lowest
risk group. The recently approved strain B. xylanisolvens DSM
23964 was first analyzed by Ulsemer and colleagues in 2011
(Ulsemer et al., 2012a,b). They isolated this strain from human
feces and performed several analytical techniques to verify that
it was new. Biochemical characteristics (no catalase activity,
no indole production, and incapable of degrading starch),
phylogenetic analysis, and DNA-DNA hybridization classified
the strain as B. xylanisolvens. So far, the performed analyses have
established no differences between the new strain and the type
strain. Finally, the Random Amplification of Polymorphic DNA
profile revealed significant differences, confirming the existence
of the new strain B. xylanisolvens DSM 23964.
Scientific Opinion of the EFSA Panel on Bacteroides
xylanisolvens DSM 23964
Following a request from the European Commission, the EFSA
Panel on Dietetic Products, Nutrition and Allergies carried out
additional assessment for pasteurized milk products fermented
with B. xylanisolvens DSM 23964 as a novel food under
Regulation (EC) No 258/97 (European Commission, 1997b).
This strain has no history of use in the food industry, and no
strain in the genus Bacteroides has a proven history of use in
food production. The novel food status is related to low-fat and
skimmed milk products fermented with B. xylanisolvens DSM
23964 as the starter culture. After fermentation, the product is
heat treated for 1 h at 75◦C, and no viable cells of B. xylanisolvens
are found in the final product.
The relevant phenotypic and genotypic data were provided by
the applicant, and the EFSA Panel considered this information
regarding the characterization of B. xylanisolvens DSM 23964
to be sufficient. The production process was clearly described
in the application, and a study to guarantee the effectiveness
of the heat treatment was conducted. Consequently, the EFSA
Panel deemed the applied techniques to be standardized across
the dairy industry, considered that they are sufficiently described,
and identified no safety concerns (EFSA Panel on Dietetic
Products, Nutrition and Allergies, 2015).
The applicant also provided the anticipated intake of the
product. The novel food would be marketed in liquid and semi-
liquid forms in fermented, low-fat milk and skimmed milk
products (fermentedmilk, buttermilk, yogurt, and yogurt drinks)
or as a spray-dried powder (the fillings and coatings of cereals,
cereal bars, fruits, and nuts). Due to a lack of European data,
the applicant used consumption data from the United States. A
conservative scenario was used to estimate the intake, proposing
that the applicant’s products would replace all existing products
(e.g., yogurt and buttermilk; EFSA Panel on Dietetic Products,
Nutrition and Allergies, 2015).
The applicant provided compositional data for spray-dried
skimmed milk cultured with B. xylanisolvens DSM 23964,
including an overview of relevant macronutrients. The applicant
also supplied an overview of the vitamin B2, vitamin B12, free
lysine, and furosine (as a marker forMaillard reaction) content to
ensure that the heat treatment had no impact on these vitamins.
Although, lactose content was missing from the analysis (a
comparable amount to traditional products was assumed), the
EFSA Panel considered consumption of the novel food to not be
nutritionally disadvantageous.
The applicant also provided toxicological information about
the novel food, including a study on an intraperitoneal abscess
formation model in mice (Ulsemer et al., 2012b). Abscess
formation is a relevant pathology because some species in the
genus Bacteroides, such as B. fragilis, can induce abscesses on
multiple sites in the body. B. xylanisolvens DSM 23964 was
TABLE 1 | General characteristics of Bacteroides xylanisolvens.
Phylum Class Order Family Genus Species
Bacteroidetes Bacteroidetes Bacteroidales Bacteroidaceae Bacteroides Bacteroides xylanisolvens
Type strain DSM 188367 (XB1AT)
Biosafety level 1
Origin Faecal sample from a healthy adult volunteer
CHARACTERISTICS
Morphology Pleomorphic, Gram-negative, rod-shaped bacterium with rounded ends,
1.8–2.5 µm (length), 0.2–0.3 µm (width), no endospores, single or paired cells, no filaments
Genome Size: 6,059 kb, ORF’s: 4,922, GC content: 41%
Physiology Chemo-organoheterotroph, mesophilic (25–42◦C—optimum 38◦C), pH optimum 6.8, obligate anaerobe
Indole negative, catalase negative, xylan positive, D-mannitol positive
No starch utilization
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administered in varying doses, but none of the mice developed
abscesses. Human studies were also supplied to the EFSA
(Ulsemer et al., 2012a,c).
Although, the applicant did not providematerial regarding the
allergenicity of the product, the EFSA panel judged that it would
be unlikely that the allergenic potential would differ from that of
other fermented dairy products. The EFSA itself had previously
considered the effect of heat treatment on the allergenicity of
milk (EFSA Panel on Dietetic Products EFSA Panel on Dietetic
Products, Nutrition and Allergies, 2014).
QPS Evaluation of B. xylanisolvens
When the EFSA receives an application for a novel bacterial
strain or a food product containing a novel strain, it conducts
a mandatory, in-depth evaluation based on the QPS scheme.
Consequently, after the EFSA Panel on Dietetic Products,
Nutrition, and Allergies was asked to perform an additional
assessment on B. xylanisolvens DSM 23964, the EFSA Panel on
Biological Hazards (BIOHAZ) conducted a QPS assessment for
B. xylanisolvens (EFSA Panel on Biological Hazards, 2014). This
panel found that the published studies about B. xylanisolvens
were not sufficient to include the organism on the QPS list,
although no relevant safety concerns could be established.
The cepA gene in the genomic DNA of B. xylanisolvens DSM
23964 provides the strain with resistance to β-lactam antibiotics
(Ulsemer et al., 2012b). This resistance is very common in the
genus Bacteroides (Wexler, 2007). No mobile elements, such as
conjugative transposons and plasmids, were found. The strain
was also screened for 8 potential virulence genes common
in other Bacteroides species, but none was detected, and B.
xylanisolvens DSM 23964 showed no adhesion to Caco-2 cells
in the cell culture model (Ulsemer et al., 2012b). The panel
considered transfer of genes unlikely to take place due to the heat
inactivation and lack of plasmids.
The panel emphasized that the body of knowledge was
insufficient. B. xylanisolvens had no history of use in fermentation
processes, and the few existing studies were limited to fermented
milk products. Although, safety concerns do not seem likely, the
panel found the number of published studies to be too low to
definitely exclude safety issues. The pilot studies involved only
small, healthy cohorts, and the administered bacterial cells were
inactivated. Considering all these arguments, the panel did not
recommend putting B. xylanisolvens on the QPS list (EFSA Panel
on Biological Hazards, 2014).
Bacteroides xylanisolvens and Its Beneficial
Properties
Most bacteria found in the human intestine are anaerobic.
Among the many requirements for a bacterial strain to be
categorized as probiotic, an essential characteristic is survival
along the gastro-intestinal tract to finally provide beneficial
effects for the host. B. xylanisolvens DSM 23964 had a survival
rate of 90% after spending 3 h in simulated gastric juice and a
survival rate of 96% after spending 4 h in simulated intestinal
juices (Ulsemer et al., 2012b).
Immunomodulatory properties are important attributes of
probiotics. The genus Bacteroides achieved a higher induction
of mucosal IgA production than Lactobacillus when co-cultured
with Peyer’s patches lymphocytes (Yanagibashi et al., 2009).The
fermentation of dietary polysaccharides with production of SCFA
by B. xylanisolvens is connected to health-promoting effects
through lower cholesterol levels, satiety stimulation, and even an
anti-carcinogenic effect (Hosseini et al., 2011).
Published studies on fermented milk products containing B.
xylanisolvensDSM 23964 are limited to inactivated bacterial cells,
but by definition, probiotics need to be alive when administered
to the consumer. Moreover, despite this microorganism’s high
survival and ability to ferment carbohydrates, these properties
are irrelevant in the context of the approved product because it
contains a heat-killed strain; therefore, no survival or metabolic
activity is expected.
B. xylanisolvens offers several potential beneficial properties.
However, its inability to bind to epithelial cells in vitro (Ulsemer
et al., 2012b) is a major disadvantage in the assessment of
probiotic properties because the capability to bind to intestinal
epithelial cells in the host is a key step in probiotic activity.
As well, studies with living bacteria are needed to increase the
chances of acceptance as a probiotic.
Admission of B. xylanisolvens as a Novel Food:
Impact on Other Candidates
B. xylanisolvens is only the fourth bacterium, after L.
mesenteroides, B. subtilis natto, and C. butyricum, to be
approved under Novel Food Regulation No 258/97 (European
Commission, 1997b).
The positive outcome of the novel food assessment is
independent from the QPS evaluation results. B. xylanisolvens
and C. butyricum have not yet been included on the QPS list.
It should be pointed out that during the QPS assessment, only
the species itself is analyzed, and the potential food products
containing the bacteria are not of interest.
Thermal inactivated bacterial form falls out of the accepted
definitions of probiotics described above, because the viability
of bacterial cells is an essential condition. Nevertheless, non-
viable and therefore non-culturable, and immunologically active
microbial cells have been reported to provide health benefits
to consumers (de Almada et al., 2016) The use of killed
bacteria, as long as the beneficial effect is totally or partially
retained, represent and advantage when the use of live bacteria
is not authorized or may be potentially harmful for some
individuals such as patients with weak immune system or
under inflammatory conditions (Taverniti and Guglielmetti,
2011; Tsilingiri and Rescigno, 2012). To define the use
of non-viable microorganisms which, when administered in
adequate amounts, confer a benefit on the consumer the term
“paraprobiotic” has been proposed (Taverniti and Guglielmetti,
2011; de Almada et al., 2016), but it still is not a wide
accepted and employed term by scientific community and
institutions.
Several mechanistic studies have demonstrated that specific
chemical compounds isolated from bacteria can induce specific
immune responses (Taverniti and Guglielmetti, 2011). In these
cases, the term “postbiotic” has been proposed to refer any
factor resulting from the metabolic activity of a bacteria or
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any released bacterial molecule capable of conferring beneficial
effects to the consumer in a direct or indirect way (Tsilingiri
and Rescigno, 2012; de Almada et al., 2016). But, similarly
with “parabiotic” concept is not an officially accepted and used
term.
The acceptance of the thermal inactivated form of B.
xylanisolvens as a novel food may pave the way for other novel
microorganisms in non-viable form or novel bacterial molecules
to exert positive health impacts.
Akkermansia muciniphila
The relatively newly described species A. muciniphila is the first
discovered taxonomic member in the genus Akkermansia. By
June 2017, there has been no evaluation according to the QPS
status, which would be performed and published by EFSA. Due
to the recent description of this microorganism, it has no history
of use in the food industry, so it must be treated according to the
Novel Food Regulation (European Commission, 1997b).
A. muciniphila was discovered in 2004 during the search for
new mucus-degrading bacteria in human fecal samples. The
newly isolated organism was named after Antoon Akkermans,
a well-respected Dutch microbiologist who has made significant
contributions to the field of microbial ecology (Belzer and De
Vos, 2012). This oval-shaped, Gram-negative microorganism
belongs to the phylum Verrucomicrobia. A. muciniphila
further belongs to the class Verrucomicrobiae, the order
Verrucomicrobiales, and the family Verrucomicrobiaceae. A.
muciniphila was originally classified as a strict anaerobe, but
in the same way as other anaerobic gut colonizers such
as Bacteroides fragilis and Bifidobacterium adolescentis, A.
muciniphila can tolerate small amounts of oxygen and even can
use it at low oxygen concentrations (Ouwerkerk et al., 2016b).
This contrasts with some of the butyrate producing bacteria that
are really strict anaerobes.
Metagenomic analysis have indicated that at least 8 additional
A. muciniphila-related species are present in the human intestine
(van Passel et al., 2011). Belzer and de Vos suggested that the
genus Akkermansia consists of 5 distinct clades (Belzer and
De Vos, 2012). Four of these 5 clades are associated with A.
muciniphila, with sequence similarity range of 80–100%.
Nearly all investigated mammals showed Akkermansia-
related sequences in their intestinal samples. Akkermansia-
derived sequences are not limited to mammals but also
found in other vertebrates: similar sequences were detected
in zebrafish and the Burmese python (Costello et al., 2010;
Roeselers et al., 2011). From the latter a new species,
Akkermansia glyciniphila was isolated and characterized from
reticulated python (Ouwerkerk et al., 2016a, 2017). These
ubiquitous findings suggest that Akkermansia played a crucial
role in the early stages of vertebrata evolution and that
its presence might be related to essential functions in the
intestine.
Genomic analyses revealed that the single chromosome of
A. muciniphila has 2,176 genes with a GC content of 55.8%
(Donohue and Salminen, 1996). The secretome responsible
for the degradation of mucin involves 61 different proteins,
representing 11% of the total protein content (Belzer and De Vos,
2012).
Akkermansia is a relatively new genus, so it is expected that
additional species similar to A. muciniphila will be found in
coming years as is illustrated by the discovery ofA. glyciniphila. It
obviously has no history of use in the food sector, and its potential
areas of application should be explored.
Despite the short time since the discovery of Akkermansia, its
basic characteristics are well-known. This organism is non-motile
and specialized in degrading mucin. A. muciniphila is anaerobe
and chemo-organotroph and can use mucin as its sole nitrogen,
carbon and energy source (Derrien et al., 2004). The habitat of
Akkermansia spp. is also well-documented due to its ubiquitous
occurrence in the intestines of many vertebrates (Belzer and De
Vos, 2012). The general properties of A. muciniphila are listed in
Table 2.
Safety Aspects
A. muciniphila is a common inhabitant of the human intestine,
accounting for 1–4% of the overall colon microbiota (Derrien
et al., 2008). Currently, there are no published clinical human
trials in which viable cells were administered to people. Such
studies have been conducted only with animal models (Everard
et al., 2013). Lagier and colleagues reported two cases in humans
where A. muciniphila accounted for up to 80% of the total
TABLE 2 | General characteristics of Akkermansia muciniphila -adapted from Gomez-Gallego et al. (2016).
Phylum Class Order Family Genus Species
Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Verrucomicrobiaceae Akkermansia Akkermansia muciniphila
Type strain MucT (ATCC BAA-835)
Biosafety level 1
Origin Faecal sample from a healthy adult volunteer
CHARACTERISTICS
Morphology Gram-negative, oval-shaped, non-motile
Genome Size: 2,664,102 bp, ORF’s: 2,176, GC content: 55.8%
Physiology Chemo-organotrophic, anaerobic, mesophilic (20–40◦C—optimum 37◦C)
Capable of using mucin as energy, nitrogen, and carbon source; mucolytic in pure culture
Sulfate release in free form from mucin fermentation
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intestinal microbiota without any noticeable decline in health
(Lagier et al., 2015), and there is no evidence that A. muciniphila
is connected to any specific disease (Derrien et al., 2010).
There are general concerns because Akkermansia shows
pathogen-like behavior. Adhesion to mucus is considered to be
a crucial step during infection but is also a behavior found in
several probiotics. In contrast to pathogens, A. muciniphila, as
a mucin degrader, stays in the outer layer of the mucus and
never reaches the inner layer, which is necessary for a successful
infection (Gomez-Gallego et al., 2016). In addition, mucin
degradation itself resembles pathogen-like behavior (Donohue
and Salminen, 1996) but is regarded as a regular process
in a balanced, self-renewing intestine (Gomez-Gallego et al.,
2016).
Colorectal cancer patients showed a four-fold increase of
A. muciniphila in stool samples compared to healthy subjects
(Weir et al., 2013). However, patients with colorectal cancer have
reduced food intake, and studies have demonstrated that fasting
correlates with increased levels of A. muciniphila (Remely et al.,
2015). In addition, colorectal cancer is related to increased cell
proliferation and mucus production; therefore, it is evident that
levels of the main mucus-degrading bacterium could increase in
this situation (Gomez-Gallego et al., 2016).
Overall, there seem to be no specific safety concerns regarding
the genus Akkermansia and its type strain A. muciniphila
MucT. Potential future concerns could be eliminated through
individual, case-by-case review. There are no applications so far
for A. muciniphila and, therefore, no history of safe use, so the
QPS status of this species has not yet been determined.
Akkermansia Muciniphila as Candidate for Novel
Food
Currently, there are no pending applications for products
containing A. muciniphila under Regulation (EC) 258/97
(European Commission, 1997b). A. muciniphila was only
discovered and isolated in 2004, so comprehensive research is still
needed to better understand this microorganism.
A. muciniphila was not used for human consumption to
any “significant degree” in the EU before 15 May 1997.
A food business operator interested in putting a product
containing A. muciniphila in the market would have to submit
an application according to the Novel Food Regulation. The
European Commission published Recommendation (European
Commission, 1997a) to give food companies the information
needed for a successful application. In the case of A. muciniphila,
there are still many unknown aspects that are needed for Novel
Food application, as well as some limitations: (1) specification of
the possible novel products which will contain A. muciniphila;
(2) production processes to keep A. muciniphila alive in the final
product to fulfill its potential probiotic properties; (3) anticipated
human intake taking into account the lack of known intake
patterns; (4) the lack of clinical trials in humans (toxicological
and nutritional assessments have been conducted only with
animal models); and (5) the lack of knowledge about the
allergenic potential.
Based on the knowledge acquired so far, though, this
microorganism could be very interesting for food companies
and consumers. A. muciniphila is part of the gut microbiota
in all humans and may display probiotic properties due to its
contribution to the functional gastro-intestinal tract. In addition,
current data indicate that a decline in A. muciniphila in the
colon correlates with several diseases, such as obesity, type-2
diabetes, and inflammatory bowel disease (Png et al., 2010; Cani
and Everard, 2014; Schneeberger et al., 2015). This reduction
could be related with a decrease in mucus thickness. But the
complex relation between A. muciniphila and the mucus layer
remains unclear and the administration of A. muciniphila might
stimulate the recovery of the mucus layer (Everard et al.,
2013).
Recently, A. muciniphila has been demonstrated to provide
beneficial effects even after heat treatment for 30 min at
70◦C. The heat-inactivated bacteria could reduce fat mass
development, insulin resistance, and dyslipidemia in obese
and diabetic mice. Some membrane proteins showed stability
and interaction with Toll-like receptor 2 even during the
thermal process. This membrane protein also improved the gut
barrier and provided ongoing beneficial effects after bacterial
inactivation (Plovier et al., 2017). Like B. xylanisolvens, therefore,
A. muciniphila may enter the food market in this non-
viable form.
The link between obesity and decreased levels of A.
muciniphila extends beyond rodents. A Swedish investigation
showed that obese pre-school children have significantly lower
levels ofA. muciniphila than their normal-weight peers (Karlsson
et al., 2012). Similarly, pre-school infants that used macrolide
antibiotics showed a higher BMI than the non-antibiotic users
and this was associated with a depletion of A.muciniphila
(Korpela et al., 2016).
Despite the growing attention to A. muciniphila, much
research is needed to gain more specific and age-restricted
information. No randomized, double-blind, placebo-controlled
human clinical trials have studied the effects of A. muciniphila
intake. Most research has involved animals, and long-term
studies on the human level are the next step to take. Despite
the lack of information relevant to the European Commission’s
recommendation on novel food, the microorganism has quite
promising prospects for future novel food applications, especially
for its potential probiotic health benefits.
It is important to point out that A. muciniphila has been
detected in breast tissue (Urbaniak et al., 2014) and then has
been consumed by humans via breast milk (Collado et al., 2012).
The question, therefore, arises whether it is necessary to prove
the safety of an organism that is already part of nutrition in
the early stages of life. However, the levels of viable cells in
breast milk might be much lower than those added to food
products. Safety concern may arise due not to the nature of
A. muciniphila but to the levels used in food and supplements.
However, assuming around 1013 bacteria to be present in the
human intestine, an average healthy adult may carry over 1011
Akkermansia in its colon. Further discussions are needed, but for
such specific cases, European legislation needs to be modified in
the future. Placement of A. muciniphila on the QPS list under the
given conditions may be complicated because a history of safe use
cannot be established.
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Fructophilic Lactic Acid Bacteria: New
Members of the Family
Characteristics
Long before Orla-Jensen described the group of lactic acid
bacteria (LAB) in 1919, humankind benefited from their positive
attributes in various food production processes (von Wright,
2012). LAB are involved in various industrial fermentation
processes, such as fermented milk products and sausages. Along
with fermented food production, the growing sector of probiotics
represents the biggest operational area for LAB.
Fructophilic lactic acid bacteria (FLAB) constitute a subgroup
in the diverse LAB order. FLAB preferably use fructose
as a substrate. They show poor growth on glucose, and
external electron acceptors (e.g., pyruvate, oxygen, and fructose)
dramatically enhance their growth. FLAB, therefore, inhabit
fructose-rich niches: flowers, fruits, fermented foods, such as
wine and cocoa beans, and even the gastro-intestinal tracts of
insects harbor these microorganisms (Endo, 2012). The FLAB
group is divided into the genera Fructobacillus (its type species:
F. fructosus) and Lactobacillus (Endo et al., 2009).
Four Fructobacillus species formerly were members of the
genus Leuconostoc, but recent analyses suggested that their
unique characteristics and phylogenetic positions supported
reclassification of this bacterial group (Endo and Okada, 2008).
Fructobacillus shows a clear preference for fructose over glucose
(Endo and Okada, 2008). Several findings related to metabolism,
genome size, and gene losses suggest reductive evolution in
Fructobacillus genus compared to Leuconostoc, providing strong
support for the reclassification and renaming of Fructobacillus
(Endo et al., 2015).
The number of species in FLAB subgroup is growing in both
genera, Fructobacillus and Lactobacilllus. Fructobacillus consists
of five species: F. fructosus, F. pseudoficulneus, F. ficulneus,
F. durionis, and F. tropaeoli (Endo et al., 2015). F. fructosus
and F. pseudoficulneus are the most frequently detected species
in natural sources. These microorganisms have been isolated
from figs, bananas, flowers, the honeybee gut, wine, and even
taberna, a traditional beverage in Southern Mexico (Alcantara-
Hernandez et al., 2010; Endo, 2012). The FLAB members in the
genus Lactobacillus are L. kunkeei, L. apinorum, and L. florum
(Neveling et al., 2012). L. kunkeei was originally isolated from
wine and characterized as obligately FLAB (Endo et al., 2012).
Interestingly, this microorganism is the major component in
the gut microbiota of honeybees (Endo and Salminen, 2013). L.
apinorum is a recently described species from honeybees, and its
fructophilic characteristic were recently reported (Maeno et al.,
2017). These two lactobacilli share 98.9% sequence similarity
based on 16S rRNA gene sequences. The genomic characteristics
of the two species, especially the gene reduction system,
are similar to Fructobacillus spp. but not to other members
of lactobacilli, suggesting that fructose-richness induced an
environment-specific gene reduction in phylogenetically distant
microorganisms (Maeno et al., 2016). L. florum was formerly the
only facultatively FLAB. It is differentiated from the obligately
FLAB based on the growth ratio on glucose. L. florum growsmore
slowly on glucose than fructose. Like obligately FLAB, electron
acceptors enhance growth on glucose.
Practical Impact and Safety
Although, FLAB were only recently discovered, this group of
microorganisms might have great potential for the food industry.
LAB are generally considered to be safe and have been involved
in human food production and nutrition since ancient times (von
Wright, 2012). These properties might be extended to FLAB.
Recent investigations detected the presence of FLAB in many
different food items. For example, several Fructobacillus spp. have
been observed during the spontaneous cocoa bean fermentation
process (Lefeber et al., 2011; Papalexandratou et al., 2011), and L.
florum has been found in grapes and wine, possibly contributing
important properties from an oenological perspective (Mtshali
et al., 2012).
The presence of FLAB in the gastro-intestinal tracts of bees,
giant ants, tropical fruit flies, and bumblebees indicate possible
probiotic characteristics (Endo, 2012), although FLAB has not
been detected in vertebrates’ intestines (Endo and Salminen,
2013). Bee commensal L. kunkeei is considered to be a candidate
for honeybee probiotics and paratransgenesis. There is no clinical
evidence regarding the pathogenicity of FLAB, whichmight be an
indicator of potential safety. However, this possibility should be
treated cautiously because consumers’ level of exposure to this
bacterial group through food is not well known. Recent studies
have suggested that administration of heat-killed L. kunkeeiYB38
has potential beneficial properties for human health, including
increased bowel movements and enhanced immunoglobulin A
production (Asama et al., 2015, 2016). As in the case of B.
xylanisolvens, therefore, L. kunkeei might enter the food market
in thermal-treated form.
Faecalibacterium prausnitzii
Fusobacterium prausnitzii is the sole member of the genus
Faecalibacterium and a commensal bacterium of the human
gut microbiota (Miquel et al., 2013). This Gram-positive,
obligately anaerobe microorganism belongs to class Clostridia.
It accounts for 3–5% of total fecal bacteria and, therefore, is
a predominant species in human feces (Breyner et al., 2017).
F. prausnitzii is a non-motile, non-spore-forming bacterium
and extremely sensitive to oxygen (Foditsch et al., 2014). F.
prausnitzii was initially classified as F. prausnitzii, but the
sequence of the 16s rRNA gene established that it is only distantly
related to Fusobacterium and more closely related to members
of Clostridium cluster IV (Miquel et al., 2013). The general
properties of F. prausnitzii are listed in Table 3.
F. prausnitzii can digest dietary fibers producing mostly
butyrate, along with other SCFA (Miquel et al., 2013), and
has been shown to respond to prebiotic supplementation using
a mixed chain length fructan supplement and pectin (Scott
et al., 2015). This microbe may play a crucial role in human
health because changes in levels of F. prausnitzii have been
associated with several gastrointestinal diseases, such as Crohn’s
disease, and depressive disorders (Miquel et al., 2013; Jiang
et al., 2015). The microorganism also displays beneficial anti-
inflammatory effects on the host, suggesting that it may be
used to counterbalance the dysbiosis linked to certain diseases
(Sokol et al., 2008; Jiang et al., 2015; Miquel et al., 2015).
Butyrate has several beneficial effects on the host, including
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TABLE 3 | General characteristics of Faecalibacterium prausnitzii.
Phylum Class Order Family Genus Species
Firmicutes Clostridia Clostridiales Clostridiaceae Faecalibacterium Faecalibacterium prausnitzii
Type strain ATCC 27768
Biosafety level 1
Origin Faecal sample from a healthy adult volunteer
CHARACTERISTICS
Morphology Gram-positive, obligately anaerobe, oval-shaped, non-motile, non-spore-forming
Genome Size: 3.05 Mb, ORF’s: 2,745, GC content: 56.4%
Physiology Chemo-organotrophic, anaerobic, mesophilic (optimum 37◦C), pH for growth ranges between 5.7 and 6.7
Butyrate, D-lactate, and formate production during glucose fermentation
Can utilize pectin, uronic acid, and host-derived substrates for growth
provision of an energy source for epithelial cells, induction of
colonic regulatory T cells, induction of apoptosis in human
colonic carcinoma cells, inhibition of inflammatory responses
in intestinal biopsy specimens, and improvement of metabolic
syndrome.Moreover, recent investigations have revealed possible
contributions to protective mechanisms, such as self-defense
against inflammatory reactions. F. prausnitzii has been involved
in the inhibition of pro-inflammatory cytokines and the secretion
of bioactive molecules which lead to blockage of the NF-κB
pathway, showing protective effects in chemically induced colitis
mouse models (Breyner et al., 2017). Further research with
Faecalibacterium could increase knowledge about its probiotic
effects and may lead to its future use in the food industry.
The successful use of F. prausnitzii as probiotic most likely will
depend on the administrationmethod. Studies related to bacterial
resistance to gastric pH in vitro recommend oral administration
of F. prausnitzii after feeding to avoid low gastric pH (Breyner
et al., 2017). Moreover, cultivating F. prausnitzii is difficult even
in anaerobic conditions (Miquel et al., 2013).
The inclusion of Faecalibacterium on the QPS list might be
difficult due to its lack of a history of safe use and to the
multiple antibiotic resistance genes observed in Faecalibacterium
sp. isolates which could contribute to resistance dissemination
(Breyner et al., 2017). In addition, full toxicology assays and
characterization of the strain are still needed for regulatory
approval (Thomas et al., 2015).
CONCLUSIONS AND OUTLOOK
Remarks on the Candidates
A brief evaluation of the benefits and drawbacks of the new
microbial candidates based on existing knowledge is given in
Table 4. Novel microbes, including many not yet assessed in
humans, are increasingly proposed as potential probiotics and
assessed as novel food. The introduction of these new species
further challenges the traditional selection criteria because the
question of their safety and efficacy arises in an untraditional
manner, with no previous experience in exposure to these
bacteria or their use in foods or supplements. Most probiotics
belong to well-known microbial groups (lactobacilli and
bifidobacteria) with long histories of safe use, which facilitates
preliminary evaluation of their safety and functionality based on
the available body of knowledge about these groups. However,
some newly proposed probiotics were first described, cultured,
and isolated during the past decade and thus present a challenge
to both scientific and regulatory frontiers. Nevertheless, A.
muciniphila, FLAB, and F. prausnitzii are regarded as promising
candidates. The many proven and potential probiotic properties
provide good opportunities for future food authorizations, but
their safety in human trials still must be demonstrated.
In the context to the definition of probiotics, Plovier and
colleagues made an especially interesting observation: even the
pasteurized and non-replicating Akkermansia cells were capable
of providing beneficial effects. Decreased fat-mass development,
dyslipidaemia, and insulin resistance were demonstrated in obese
and diabetic mice (Everard et al., 2013). This new insight
might have crucial relevance and allow future authorizations
because nonviable cells pose rise fewer concerns than living
bacteria. Nonviable bacteria are more easily deemed safe in
novel food evaluation, albeit usually in case-by-case decisions.
In comparison to B. xylanisolvens, some information about A.
muciniphila is still lacking. Due to the absence of practical
applications, specification of the novel food and its production
process and nutritional information has not yet been performed.
However, there is information available about its taxonomy,
culturing methods, pathogenic and toxicological nature, and
nutritional assessment data in animal models (Donohue and
Salminen, 1996). A major key for the approval of novel food is a
sufficient number of clinical trials in humans, but A. muciniphila
lacks enough appropriate human studies. Randomized, double-
blind, placebo-controlled clinical trials, dose-response studies,
and toxicological studies are still needed to, for example, establish
the appropriate number of bacteria to be administered and
the right matrix to provide probiotic properties. If the missing
data become available, though, A. muciniphila has similar
chances of acceptance as a novel food as the recently officially
accepted B. xylanisolvens. Notably the EFSA positively assessed
B. xylanisolvens although the applicant supplied only two human
studies.
FLAB were also discovered and described recently, so it
is challenging to predict how they might be accepted as
part of future food products. Further research is needed to
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TABLE 4 | Examples of potential future probiotics suggested for human use and/or assessed as novel foods in the European Union.





















Protective effect on gastric ulcers
Modulation of lipid profile, insulin
resistance and colon homeostasis
Nakanishi et al., 2003;
Shinnoh et al., 2013; Zhao
et al., 2014; Wang et al.,
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Toxicity and safety assessment
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assessment
Mirande et al., 2010;
Ulsemer et al., 2012a,b,c,
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1996; Everard et al., 2013;
Reunanen et al., 2015;
Schneeberger et al., 2015;
















Reduction of microbial pathogens Endo et al., 2009, 2010;


















Increase of plasma anti-Th17
cytokines and suppression of IL-17
levels in both plasma and colonic
mucosa
Normalization of altered colonic
permeability Protective effect
against colitis
Miquel et al., 2013; Zhang
et al., 2013; Laval et al.,
2015; Ulluwishewa et al.,
2015; Quevrain et al., 2016
The table includes some selected examples of reported positive health effects based on in vitro and in vivo studies.
understand, for example, what differentiates this bacterium
from traditional LAB and its exact relevance to the production
of fermented foods. Recent studies revealed that heat-killed
L. kunkeei possess beneficial properties, such as increased
bowel movement and enhanced immunoglobulin A production
(Asama et al., 2015, 2016). Their special relation to LAB, a
very widely used group in the food industry, may lead to
inclusion on the QPS list and novel food authorization in the
future.
The growing amount of evidence supporting that the
modulation of F. prausnitzii levels using prebiotics, probiotics,
and symbiotics might have prophylactic or therapeutic
applications in human health makes this bacterium interesting
from the perspective of novel foods. Factors such as sensitivity to
oxygen, gastric pH, and bile salts and industrial production for
probiotic use need to be optimized, and toxicological assays and
antibiotic resistance tests should be carefully conducted before
clinical trials in humans.
The potential candidates for novel foods discussed as
examples in the present work represent only a small fraction of
the potential bacteria that may be included in novel foods in
the future. Other potential candidates are Eubacterium hallii and
bacteria in the genus Roseburia. E. hallii is a common inhabitant
of the human gut microbiota and is known for its versatile
utilization of different carbon sources. E. hallii can produce
butyrate from lactate, acetate, and glucose and is one of the
first butyrate producers in the infant gut (Pham et al., 2016). In
addition, a recent study showed the impact of E. hallii in treating
insulin resistance in a mouse model (Udayappan et al., 2016).
Its early appearance in the human intestine and production of
essential SCFA may enable future novel food applications in the
food industry.
The genus Roseburia consists of five species which are
Gram-positive, obligately anaerobic bacteria and motile due to
the presence of subterminal flagella (Tamanai-Shacoori et al.,
2017). Roseburia spp. are a dominant intestinal bacterial species,
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accounting for 2–15% of the total human gut microbiota that
produce SCFA (Dostal et al., 2015). Considering the production
of essential SCFA and the high levels of Roseburia spp. in
the human microbiota, members of this genus may have great
potential as future novel probiotics.
Remarks on Regulatory Aspects
Ongoing revisions of the regulations on novel food, along with
the continuous updating of the QPS list, will accelerate novel
food authorization and biological agent safety assessment. Both
processes support the work of the EFSA and access to novel
products in the food market and ensure the safety of the
European consumer. The lengthy process to revise the novel
food regulations has demonstrated the difficulty of changing
legislation on the European level. Most decisions need to
be unanimous, and it is challenging to please all member
states. Although, these developments are remarkable, the EU
authorization of novel food still seems more comprehensive
than the GRAS concept in the United States. The precautionary
principle is a fundamental pillar of environmental, food, and
health policies in the EU. Prevention of any possible harm
or danger to the consumer is the most important priority,
especially for marketing of food containing potentially harmful
bacteria. The elimination of any possible health threat, therefore,
is essential before a product is allowed to enter the European
market. The European consumer is the most relevant player
in European legislation although companies understandably
complain about such strict conditions.
Regulation (EU) 2015/2283 on novel foods (European
Commission, 2015), which will come into force on January 1,
2018, is aimed at facilitating the authorization of novel food. The
EFSA is responsible for the scientific risk assessment, ensuring
the shift from an individual assessment by the national competent
authorities to a generic assessment. The new regulation also
directs the EFSA to deliver scientific opinions within 9 months
after receiving all valid applications. This mandate represents
enormous time savings and a significant decrease in the
financial costs for food companies submitting applications. The
newly introduced data protection for approved novel food
authorization will also help companies successfully compete in
the food market.
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